Novel therapies for chronic myelogenous leukemia

Author： Jahagirdar B.N.   Miller J.S.   Shet A.   Verfaillie C.M.  

Publisher： Elsevier

ISSN： 0301-472X

Source： Experimental Hematology, Vol.29, Iss.5, 2001-05, pp. : 543-556

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hematology clinic: chronic myelogenous leukemia

By Weber Alissa A.   Talpaz Moshe  

Hematology, Vol. 18, Iss. 6, 2013-11 ,pp. : 371-372

Maney Publishing

Access to resources Recommend Favorite

Allogeneic transplantation for chronic myelogenous leukemia

By McGlave Philip  

Hematology, Vol. 10, Iss. 1, 2005-09 ,pp. : 15-18

Maney Publishing

Access to resources Recommend Favorite

Rho-Signaling Pathways in Chronic Myelogenous Leukemia

By  

Cardiovascular & Haematological Disorders - Drug Targets(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders), Vol. 8, Iss. 4, 2008-12 ,pp. : 261-267

Bentham Science Publishers

Access to resources Recommend Favorite

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

By Giles F.J.   Feldman E.J.   Roboz G.J.   Larson R.A.   Mamus S.W.   Cortes J.E.   Verstovsek S.   Faderl S.   Talpaz M.   Beran M.   Albitar M.   O'Brien S.M.   Kantarjian H.M.  

Leukemia Research, Vol. 27, Iss. 12, 2003-12 ,pp. : 1091-1096

Elsevier

Access to resources Recommend Favorite

Posttransplantation epstein-barr viral meningitis in a patient with chronic myelogenous leukemia

By Kanamori Heiwa   Fujisawa Shin   Yamaji Satoshi   Tanaka Masatsugu   Tomita Naoto   Fujimaki Katsumichi   Ishigatsubo Yoshiaki  

International Journal of Hematology, Vol. 74, Iss. 4, 2001-12 ,pp. : 473-474

Springer Publishing Company

Access to resources Recommend Favorite